ID   PLCG1_HUMAN             Reviewed;        1290 AA.
AC   P19174; B7ZLY7; B9EGH4; E1P5W4; Q2V575;
DT   01-NOV-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1990, sequence version 1.
DT   07-APR-2021, entry version 249.
DE   RecName: Full=1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 {ECO:0000305};
DE            EC=3.1.4.11 {ECO:0000250|UniProtKB:P10686};
DE   AltName: Full=PLC-148;
DE   AltName: Full=Phosphoinositide phospholipase C-gamma-1;
DE   AltName: Full=Phospholipase C-II;
DE            Short=PLC-II;
DE   AltName: Full=Phospholipase C-gamma-1;
DE            Short=PLC-gamma-1;
GN   Name=PLCG1 {ECO:0000312|HGNC:HGNC:9065}; Synonyms=PLC1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND PHOSPHORYLATION.
RC   TISSUE=Brain, and Vein;
RX   PubMed=2167438; DOI=10.1128/mcb.10.9.4770;
RA   Burgess W.H., Dionne C.A., Kaplow J.M., Mudd R., Friesel R.,
RA   Zilberstein A., Schlessinger J., Jaye M.;
RT   "Characterization and cDNA cloning of phospholipase C-gamma, a major
RT   substrate for heparin-binding growth factor 1 (acidic fibroblast growth
RT   factor)-activated tyrosine kinase.";
RL   Mol. Cell. Biol. 10:4770-4777(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ASN-209; GLY-279; THR-739
RP   AND THR-813.
RG   NIEHS SNPs program;
RL   Submitted (NOV-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D.,
RA   Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G.,
RA   Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E.,
RA   Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D.,
RA   Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M.,
RA   Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D.,
RA   Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M.,
RA   Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A.,
RA   Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L.,
RA   Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L.,
RA   Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   THR-813.
RC   TISSUE=Brain, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   INTERACTION WITH FGFR1.
RX   PubMed=1656221; DOI=10.1128/mcb.11.10.5068;
RA   Mohammadi M., Honegger A.M., Rotin D., Fischer R., Bellot F., Li W.,
RA   Dionne C.A., Jaye M., Rubinstein M., Schlessinger J.;
RT   "A tyrosine-phosphorylated carboxy-terminal peptide of the fibroblast
RT   growth factor receptor (Flg) is a binding site for the SH2 domain of
RT   phospholipase C-gamma 1.";
RL   Mol. Cell. Biol. 11:5068-5078(1991).
RN   [7]
RP   PHOSPHORYLATION AT SER-1248.
RX   PubMed=1370476;
RA   Park D.J., Min H.K., Rhee S.G.;
RT   "Inhibition of CD3-linked phospholipase C by phorbol ester and by cAMP is
RT   associated with decreased phosphotyrosine and increased phosphoserine
RT   contents of PLC-gamma 1.";
RL   J. Biol. Chem. 267:1496-1501(1992).
RN   [8]
RP   INTERACTION WITH FGFR4.
RX   PubMed=7518429;
RA   Vainikka S., Joukov V., Wennstrom S., Bergman M., Pelicci P.G., Alitalo K.;
RT   "Signal transduction by fibroblast growth factor receptor-4 (FGFR-4).
RT   Comparison with FGFR-1.";
RL   J. Biol. Chem. 269:18320-18326(1994).
RN   [9]
RP   PHOSPHORYLATION AT TYR-771 AND TYR-783 BY SYK, AND INTERACTION WITH SYK.
RX   PubMed=8657103; DOI=10.1128/mcb.16.4.1305;
RA   Law C.L., Chandran K.A., Sidorenko S.P., Clark E.A.;
RT   "Phospholipase C-gamma1 interacts with conserved phosphotyrosyl residues in
RT   the linker region of Syk and is a substrate for Syk.";
RL   Mol. Cell. Biol. 16:1305-1315(1996).
RN   [10]
RP   INTERACTION WITH KIT.
RX   PubMed=9038210; DOI=10.1074/jbc.272.9.5915;
RA   Price D.J., Rivnay B., Fu Y., Jiang S., Avraham S., Avraham H.;
RT   "Direct association of Csk homologous kinase (CHK) with the
RT   diphosphorylated site Tyr568/570 of the activated c-KIT in
RT   megakaryocytes.";
RL   J. Biol. Chem. 272:5915-5920(1997).
RN   [11]
RP   INTERACTION WITH AXL.
RX   PubMed=9178760; DOI=10.1038/sj.onc.1201123;
RA   Braunger J., Schleithoff L., Schulz A.S., Kessler H., Lammers R.,
RA   Ullrich A., Bartram C.R., Janssen J.W.;
RT   "Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is
RT   mediated mainly by a multi-substrate docking-site.";
RL   Oncogene 14:2619-2631(1997).
RN   [12]
RP   INTERACTION WITH LAT.
RX   PubMed=9489702; DOI=10.1016/s0092-8674(00)80901-0;
RA   Zhang W., Sloan-Lancaster J., Kitchen J., Trible R.P., Samelson L.E.;
RT   "LAT: the ZAP-70 tyrosine kinase substrate that links T cell receptor to
RT   cellular activation.";
RL   Cell 92:83-92(1998).
RN   [13]
RP   INTERACTION WITH SHB.
RX   PubMed=10488157; DOI=10.1074/jbc.274.39.28050;
RA   Lindholm C.K., Gylfe E., Zhang W., Samelson L.E., Welsh M.;
RT   "Requirement of the Src homology 2 domain protein Shb for T cell receptor-
RT   dependent activation of the interleukin-2 gene nuclear factor for
RT   activation of T cells element in Jurkat T cells.";
RL   J. Biol. Chem. 274:28050-28057(1999).
RN   [14]
RP   PHOSPHORYLATION BY KDR.
RX   PubMed=10102632; DOI=10.1038/sj.onc.1202478;
RA   Dougher M., Terman B.I.;
RT   "Autophosphorylation of KDR in the kinase domain is required for maximal
RT   VEGF-stimulated kinase activity and receptor internalization.";
RL   Oncogene 18:1619-1627(1999).
RN   [15]
RP   INTERACTION WITH TNK1.
RX   PubMed=10873601; DOI=10.1006/bbrc.2000.2887;
RA   Felschow D.M., Civin C.I., Hoehn G.T.;
RT   "Characterization of the tyrosine kinase Tnk1 and its binding with
RT   phospholipase C-gamma1.";
RL   Biochem. Biophys. Res. Commun. 273:294-301(2000).
RN   [16]
RP   INTERACTION WITH HEPATITIS E VIRUS/HEV PROTEIN ORF3 (MICROBIAL INFECTION).
RX   PubMed=11518702; DOI=10.1074/jbc.m101546200;
RA   Korkaya H., Jameel S., Gupta D., Tyagi S., Kumar R., Zafrullah M.,
RA   Mazumdar M., Lal S.K., Xiaofang L., Sehgal D., Das S.R., Sahal D.;
RT   "The ORF3 protein of hepatitis E virus binds to Src homology 3 domains and
RT   activates MAPK.";
RL   J. Biol. Chem. 276:42389-42400(2001).
RN   [17]
RP   INTERACTION WITH RALGPS1.
RX   PubMed=10747847; DOI=10.1074/jbc.c000085200;
RA   Rebhun J.F., Chen H., Quilliam L.A.;
RT   "Identification and characterization of a new family of guanine nucleotide
RT   exchange factors for the ras-related GTPase Ral.";
RL   J. Biol. Chem. 275:13406-13410(2000).
RN   [18]
RP   PROBABLE DEPHOSPHORYLATION BY PTPRJ.
RX   PubMed=11259588; DOI=10.1128/mcb.21.7.2393-2403.2001;
RA   Baker J.E., Majeti R., Tangye S.G., Weiss A.;
RT   "Protein tyrosine phosphatase CD148-mediated inhibition of T-cell receptor
RT   signal transduction is associated with reduced LAT and phospholipase
RT   Cgamma1 phosphorylation.";
RL   Mol. Cell. Biol. 21:2393-2403(2001).
RN   [19]
RP   PHOSPHORYLATION AT TYR-783, AND SUBCELLULAR LOCATION.
RX   PubMed=11564877; DOI=10.1128/mcb.21.20.6939-6950.2001;
RA   Veri M.C., DeBell K.E., Seminario M.C., DiBaldassarre A., Reischl I.,
RA   Rawat R., Graham L., Noviello C., Rellahan B.L., Miscia S., Wange R.L.,
RA   Bonvini E.;
RT   "Membrane raft-dependent regulation of phospholipase Cgamma-1 activation in
RT   T lymphocytes.";
RL   Mol. Cell. Biol. 21:6939-6950(2001).
RN   [20]
RP   PROBABLE DEPHOSPHORYLATION BY PTPRJ.
RX   PubMed=12913111; DOI=10.1083/jcb.200303040;
RA   Lin J., Weiss A.;
RT   "The tyrosine phosphatase CD148 is excluded from the immunologic synapse
RT   and down-regulates prolonged T cell signaling.";
RL   J. Cell Biol. 162:673-682(2003).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-771 AND TYR-1253, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=15144186; DOI=10.1021/ac035352d;
RA   Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M.,
RA   Peters E.C.;
RT   "Robust phosphoproteomic profiling of tyrosine phosphorylation sites from
RT   human T cells using immobilized metal affinity chromatography and tandem
RT   mass spectrometry.";
RL   Anal. Chem. 76:2763-2772(2004).
RN   [22]
RP   INTERACTION WITH NTRK1.
RX   PubMed=15488758; DOI=10.1016/j.ccr.2004.09.011;
RA   Tacconelli A., Farina A.R., Cappabianca L., Desantis G., Tessitore A.,
RA   Vetuschi A., Sferra R., Rucci N., Argenti B., Screpanti I., Gulino A.,
RA   Mackay A.R.;
RT   "TrkA alternative splicing: a regulated tumor-promoting switch in human
RT   neuroblastoma.";
RL   Cancer Cell 6:347-360(2004).
RN   [23]
RP   REVIEW ON INTERACTION WITH KIT AND ROLE IN KIT SIGNALING.
RX   PubMed=15526160; DOI=10.1007/s00018-004-4189-6;
RA   Ronnstrand L.;
RT   "Signal transduction via the stem cell factor receptor/c-Kit.";
RL   Cell. Mol. Life Sci. 61:2535-2548(2004).
RN   [24]
RP   INTERACTION WITH BLNK; VAV1; GRB2 AND NCK1.
RX   PubMed=15270728; DOI=10.1111/j.1365-2567.2004.01918.x;
RA   Taguchi T., Kiyokawa N., Takenouch H., Matsui J., Tang W.-R., Nakajima H.,
RA   Suzuki K., Shiozawa Y., Saito M., Katagiri Y.U., Takahashi T.,
RA   Karasuyama H., Matsuo Y., Okita H., Fujimoto J.;
RT   "Deficiency of BLNK hampers PLC-gamma2 phosphorylation and Ca2+ influx
RT   induced by the pre-B-cell receptor in human pre-B cells.";
RL   Immunology 112:575-582(2004).
RN   [25]
RP   INTERACTION WITH FLT4.
RX   PubMed=15102829; DOI=10.1074/jbc.m314015200;
RA   Wang J.F., Zhang X., Groopman J.E.;
RT   "Activation of vascular endothelial growth factor receptor-3 and its
RT   downstream signaling promote cell survival under oxidative stress.";
RL   J. Biol. Chem. 279:27088-27097(2004).
RN   [26]
RP   PHOSPHORYLATION AT TYR-783 IN RESPONSE TO KDR ACTIVATION.
RX   PubMed=15215251; DOI=10.1074/jbc.m401538200;
RA   Jia H., Bagherzadeh A., Bicknell R., Duchen M.R., Liu D., Zachary I.;
RT   "Vascular endothelial growth factor (VEGF)-D and VEGF-A differentially
RT   regulate KDR-mediated signaling and biological function in vascular
RT   endothelial cells.";
RL   J. Biol. Chem. 279:36148-36157(2004).
RN   [27]
RP   PHOSPHORYLATION BY ITK.
RX   PubMed=16081816; DOI=10.4049/jimmunol.175.4.2449;
RA   Houtman J.C., Houghtling R.A., Barda-Saad M., Toda Y., Samelson L.E.;
RT   "Early phosphorylation kinetics of proteins involved in proximal TCR-
RT   mediated signaling pathways.";
RL   J. Immunol. 175:2449-2458(2005).
RN   [28]
RP   INTERACTION WITH FGFR2, AND PHOSPHORYLATION.
RX   PubMed=16844695; DOI=10.1074/jbc.m600448200;
RA   Hatch N.E., Hudson M., Seto M.L., Cunningham M.L., Bothwell M.;
RT   "Intracellular retention, degradation, and signaling of glycosylation-
RT   deficient FGFR2 and craniosynostosis syndrome-associated FGFR2C278F.";
RL   J. Biol. Chem. 281:27292-27305(2006).
RN   [29]
RP   FUNCTION, INTERACTION WITH VIL1, AND SUBCELLULAR LOCATION.
RX   PubMed=17229814; DOI=10.1152/ajpcell.00420.2006;
RA   Wang Y., Tomar A., George S.P., Khurana S.;
RT   "Obligatory role for phospholipase C-gamma(1) in villin-induced epithelial
RT   cell migration.";
RL   Am. J. Physiol. 292:C1775-C1786(2007).
RN   [30]
RP   PHOSPHORYLATION BY FGFR3.
RX   PubMed=17561467; DOI=10.1016/j.bone.2006.11.030;
RA   Harada D., Yamanaka Y., Ueda K., Nishimura R., Morishima T., Seino Y.,
RA   Tanaka H.;
RT   "Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic
RT   dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via
RT   PLCgamma-activated STAT1.";
RL   Bone 41:273-281(2007).
RN   [31]
RP   INTERACTION WITH PDGFRB.
RX   PubMed=17620338; DOI=10.1074/jbc.m701797200;
RA   Reddi A.L., Ying G., Duan L., Chen G., Dimri M., Douillard P., Druker B.J.,
RA   Naramura M., Band V., Band H.;
RT   "Binding of Cbl to a phospholipase Cgamma1-docking site on platelet-derived
RT   growth factor receptor beta provides a dual mechanism of negative
RT   regulation.";
RL   J. Biol. Chem. 282:29336-29347(2007).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1221, PHOSPHORYLATION [LARGE
RP   SCALE ANALYSIS] AT SER-1222 (ISOFORM 2), AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [33]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [34]
RP   INTERACTION WITH FGFR3.
RX   PubMed=19286672; DOI=10.1093/hmg/ddp116;
RA   Salazar L., Kashiwada T., Krejci P., Muchowski P., Donoghue D.,
RA   Wilcox W.R., Thompson L.M.;
RT   "A novel interaction between fibroblast growth factor receptor 3 and the
RT   p85 subunit of phosphoinositide 3-kinase: activation-dependent regulation
RT   of ERK by p85 in multiple myeloma cells.";
RL   Hum. Mol. Genet. 18:1951-1961(2009).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-771; TYR-775; TYR-783 AND
RP   SER-1221, PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1222 (ISOFORM 2),
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [36]
RP   INTERACTION WITH PDGFRB, AND PHOSPHORYLATION AT TYR-771.
RX   PubMed=20494825; DOI=10.1016/j.cellsig.2010.05.004;
RA   Wardega P., Heldin C.H., Lennartsson J.;
RT   "Mutation of tyrosine residue 857 in the PDGF beta-receptor affects cell
RT   proliferation but not migration.";
RL   Cell. Signal. 22:1363-1368(2010).
RN   [37]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1221 AND TYR-1253, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [38]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [39]
RP   INTERACTION WITH FGFR1, AND PHOSPHORYLATION BY FGFR1.
RX   PubMed=21765395; DOI=10.1038/emboj.2011.234;
RA   Persaud A., Alberts P., Hayes M., Guettler S., Clarke I., Sicheri F.,
RA   Dirks P., Ciruna B., Rotin D.;
RT   "Nedd4-1 binds and ubiquitylates activated FGFR1 to control its endocytosis
RT   and function.";
RL   EMBO J. 30:3259-3273(2011).
RN   [40]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1222 (ISOFORM 2), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [41]
RP   INTERACTION WITH TESPA1.
RC   TISSUE=Thymocyte;
RX   PubMed=22561606; DOI=10.1038/ni.2301;
RA   Wang D., Zheng M., Lei L., Ji J., Yao Y., Qiu Y., Ma L., Lou J., Ouyang C.,
RA   Zhang X., He Y., Chi J., Wang L., Kuang Y., Wang J., Cao X., Lu L.;
RT   "Tespa1 is involved in late thymocyte development through the regulation of
RT   TCR-mediated signaling.";
RL   Nat. Immunol. 13:560-568(2012).
RN   [42]
RP   REVIEW ON ROLE IN FGF-ACTIVATED SIGNALING PATHWAYS.
RX   PubMed=15863030; DOI=10.1016/j.cytogfr.2005.01.001;
RA   Eswarakumar V.P., Lax I., Schlessinger J.;
RT   "Cellular signaling by fibroblast growth factor receptors.";
RL   Cytokine Growth Factor Rev. 16:139-149(2005).
RN   [43]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1221; SER-1227; SER-1233 AND
RP   SER-1263, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [44]
RP   STRUCTURE BY NMR OF SH3 DOMAIN.
RX   PubMed=7681365; DOI=10.1016/0092-8674(93)90583-c;
RA   Kohda D., Hatanaka H., Odaka M., Mandiyan V., Ullrich A., Schlessinger J.,
RA   Inagaki F.;
RT   "Solution structure of the SH3 domain of phospholipase C-gamma.";
RL   Cell 72:953-960(1993).
CC   -!- FUNCTION: Mediates the production of the second messenger molecules
CC       diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). Plays an
CC       important role in the regulation of intracellular signaling cascades.
CC       Becomes activated in response to ligand-mediated activation of
CC       receptor-type tyrosine kinases, such as PDGFRA, PDGFRB, EGFR, FGFR1,
CC       FGFR2, FGFR3 and FGFR4 (By similarity). Plays a role in actin
CC       reorganization and cell migration (PubMed:17229814).
CC       {ECO:0000250|UniProtKB:P10686, ECO:0000269|PubMed:17229814}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-4,5-
CC         bisphosphate) + H2O = 1D-myo-inositol 1,4,5-trisphosphate + a 1,2-
CC         diacyl-sn-glycerol + H(+); Xref=Rhea:RHEA:33179, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:17815, ChEBI:CHEBI:58456,
CC         ChEBI:CHEBI:203600; EC=3.1.4.11;
CC         Evidence={ECO:0000250|UniProtKB:P10686};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:33180;
CC         Evidence={ECO:0000250|UniProtKB:P10686};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol) + H2O =
CC         1D-myo-inositol 1-phosphate + a 1,2-diacyl-sn-glycerol + H(+);
CC         Xref=Rhea:RHEA:43484, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:17815, ChEBI:CHEBI:57880, ChEBI:CHEBI:58433;
CC         Evidence={ECO:0000250|UniProtKB:P10686};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43485;
CC         Evidence={ECO:0000250|UniProtKB:P10686};
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC         Evidence={ECO:0000250|UniProtKB:P10686};
CC   -!- ACTIVITY REGULATION: Activated by phosphorylation on tyrosine residues.
CC       {ECO:0000269|PubMed:1370476}.
CC   -!- SUBUNIT: Interacts with AGAP2 via its SH3 domain. Interacts (via SH2
CC       domain) with RET. Interacts with FLT1 (tyrosine-phosphorylated) (By
CC       similarity). Interacts (via SH2 domain) with FGFR1, FGFR2, FGFR3 and
CC       FGFR4 (phosphorylated). Interacts with LAT (phosphorylated) upon TCR
CC       activation. Interacts (via SH3 domain) with the Pro-rich domain of
CC       TNK1. Associates with BLNK, VAV1, GRB2 and NCK1 in a B-cell antigen
CC       receptor-dependent fashion. Interacts with CBLB in activated T-cells;
CC       which inhibits phosphorylation. Interacts with SHB. Interacts (via SH3
CC       domain) with the Arg/Gly-rich-flanked Pro-rich domains of
CC       KHDRBS1/SAM68. This interaction is selectively regulated by arginine
CC       methylation of KHDRBS1/SAM68. Interacts with INPP5D/SHIP1, THEMIS and
CC       CLNK (By similarity). Interacts with AXL, FLT4 and KIT. Interacts with
CC       RALGPS1. Interacts (via the SH2 domains) with VIL1 (phosphorylated at
CC       C-terminus tyrosine phosphorylation sites). Interacts (via SH2 domain)
CC       with PDGFRA and PDGFRB (tyrosine phosphorylated). Interacts with
CC       PIP5K1C (By similarity). Interacts with NTRK1 and NTRK2 (phosphorylated
CC       upon ligand-binding). Interacts with SYK; activates PLCG1. Interacts
CC       with GRB2, LAT and THEMIS upon TCR activation in thymocytes (By
CC       similarity). Interacts with TESPA1; the association is increased with
CC       prolonged stimulation of the TCR and may facilitate the assembly of the
CC       LAT signalosome. {ECO:0000250|UniProtKB:Q62077,
CC       ECO:0000269|PubMed:10488157, ECO:0000269|PubMed:10747847,
CC       ECO:0000269|PubMed:10873601, ECO:0000269|PubMed:15102829,
CC       ECO:0000269|PubMed:15270728, ECO:0000269|PubMed:15488758,
CC       ECO:0000269|PubMed:1656221, ECO:0000269|PubMed:16844695,
CC       ECO:0000269|PubMed:17229814, ECO:0000269|PubMed:17620338,
CC       ECO:0000269|PubMed:19286672, ECO:0000269|PubMed:20494825,
CC       ECO:0000269|PubMed:21765395, ECO:0000269|PubMed:22561606,
CC       ECO:0000269|PubMed:7518429, ECO:0000269|PubMed:8657103,
CC       ECO:0000269|PubMed:9038210, ECO:0000269|PubMed:9178760,
CC       ECO:0000269|PubMed:9489702}.
CC   -!- SUBUNIT: (Microbial infection) Interacts (via SH3 domain) with HEV ORF3
CC       protein. {ECO:0000269|PubMed:11518702}.
CC   -!- INTERACTION:
CC       P19174; P42684: ABL2; NbExp=4; IntAct=EBI-79387, EBI-1102694;
CC       P19174; P31749: AKT1; NbExp=9; IntAct=EBI-79387, EBI-296087;
CC       P19174; P10275: AR; NbExp=22; IntAct=EBI-79387, EBI-608057;
CC       P19174; Q9ULH1: ASAP1; NbExp=3; IntAct=EBI-79387, EBI-346622;
CC       P19174; O43150: ASAP2; NbExp=3; IntAct=EBI-79387, EBI-310968;
CC       P19174; Q03135: CAV1; NbExp=2; IntAct=EBI-79387, EBI-603614;
CC       P19174; P20273: CD22; NbExp=2; IntAct=EBI-79387, EBI-78277;
CC       P19174; Q9BZW8: CD244; NbExp=2; IntAct=EBI-79387, EBI-1580565;
CC       P19174; Q9H1R2: DUSP15; NbExp=2; IntAct=EBI-79387, EBI-1752795;
CC       P19174; P00533: EGFR; NbExp=6; IntAct=EBI-79387, EBI-297353;
CC       P19174; P04626: ERBB2; NbExp=5; IntAct=EBI-79387, EBI-641062;
CC       P19174; P21860: ERBB3; NbExp=4; IntAct=EBI-79387, EBI-720706;
CC       P19174; P31994: FCGR2B; NbExp=2; IntAct=EBI-79387, EBI-724784;
CC       P19174; P11362: FGFR1; NbExp=9; IntAct=EBI-79387, EBI-1028277;
CC       P19174; P21802-1: FGFR2; NbExp=9; IntAct=EBI-79387, EBI-15489960;
CC       P19174; Q13480: GAB1; NbExp=36; IntAct=EBI-79387, EBI-517684;
CC       P19174; P62993: GRB2; NbExp=2; IntAct=EBI-79387, EBI-401755;
CC       P19174; P06213: INSR; NbExp=9; IntAct=EBI-79387, EBI-475899;
CC       P19174; Q07666: KHDRBS1; NbExp=3; IntAct=EBI-79387, EBI-1364;
CC       P19174; P10721: KIT; NbExp=31; IntAct=EBI-79387, EBI-1379503;
CC       P19174; O43561: LAT; NbExp=7; IntAct=EBI-79387, EBI-1222766;
CC       P19174; Q13094: LCP2; NbExp=3; IntAct=EBI-79387, EBI-346946;
CC       P19174; Q92918: MAP4K1; NbExp=6; IntAct=EBI-79387, EBI-881;
CC       P19174; P08581: MET; NbExp=10; IntAct=EBI-79387, EBI-1039152;
CC       P19174; P09619: PDGFRB; NbExp=6; IntAct=EBI-79387, EBI-641237;
CC       P19174; P63000: RAC1; NbExp=7; IntAct=EBI-79387, EBI-413628;
CC       P19174; Q8TB24: RIN3; NbExp=3; IntAct=EBI-79387, EBI-1570523;
CC       P19174; Q8WTV0-3: SCARB1; NbExp=2; IntAct=EBI-79387, EBI-20819026;
CC       P19174; O14796: SH2D1B; NbExp=2; IntAct=EBI-79387, EBI-3923013;
CC       P19174; Q9UPX8: SHANK2; NbExp=4; IntAct=EBI-79387, EBI-1570571;
CC       P19174; Q9BYB0: SHANK3; NbExp=2; IntAct=EBI-79387, EBI-1752330;
CC       P19174; Q15036: SNX17; NbExp=2; IntAct=EBI-79387, EBI-1752620;
CC       P19174; Q07889: SOS1; NbExp=3; IntAct=EBI-79387, EBI-297487;
CC       P19174; Q07890: SOS2; NbExp=4; IntAct=EBI-79387, EBI-298181;
CC       P19174; P43405: SYK; NbExp=4; IntAct=EBI-79387, EBI-78302;
CC       P19174; Q8N1K5-1: THEMIS; NbExp=3; IntAct=EBI-79387, EBI-15102259;
CC       P19174; P09327: VIL1; NbExp=5; IntAct=EBI-79387, EBI-746958;
CC       P19174; Q71V39: EEF1A2; Xeno; NbExp=3; IntAct=EBI-79387, EBI-7645815;
CC   -!- SUBCELLULAR LOCATION: Cell projection, lamellipodium
CC       {ECO:0000269|PubMed:17229814}. Cell projection, ruffle
CC       {ECO:0000269|PubMed:17229814}. Note=Rapidly redistributed to ruffles
CC       and lamellipodia structures in response to epidermal growth factor
CC       (EGF) treatment. {ECO:0000269|PubMed:17229814}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P19174-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P19174-2; Sequence=VSP_038692;
CC   -!- DOMAIN: The SH3 domain mediates interaction with CLNK (By similarity).
CC       The SH3 domain also mediates interaction with RALGPS1
CC       (PubMed:10747847). {ECO:0000250|UniProtKB:Q62077,
CC       ECO:0000269|PubMed:10747847}.
CC   -!- PTM: Tyrosine phosphorylated in response to signaling via activated
CC       FLT3, KIT and PDGFRA (By similarity). Tyrosine phosphorylated by
CC       activated FGFR1, FGFR2, FGFR3 and FGFR4. Tyrosine phosphorylated by
CC       activated FLT1 and KDR. Tyrosine phosphorylated by activated PDGFRB.
CC       The receptor-mediated activation of PLCG1 involves its phosphorylation
CC       by tyrosine kinases, in response to ligation of a variety of growth
CC       factor receptors and immune system receptors. For instance, SYK
CC       phosphorylates and activates PLCG1 in response to ligation of the B-
CC       cell receptor. May be dephosphorylated by PTPRJ. Phosphorylated by ITK
CC       and TXK on Tyr-783 upon TCR activation in T-cells. {ECO:0000250,
CC       ECO:0000269|PubMed:10102632, ECO:0000269|PubMed:11564877,
CC       ECO:0000269|PubMed:1370476, ECO:0000269|PubMed:15215251,
CC       ECO:0000269|PubMed:16081816, ECO:0000269|PubMed:16844695,
CC       ECO:0000269|PubMed:17561467, ECO:0000269|PubMed:20494825,
CC       ECO:0000269|PubMed:2167438, ECO:0000269|PubMed:21765395,
CC       ECO:0000269|PubMed:8657103}.
CC   -!- PTM: Ubiquitinated by CBLB in activated T-cells.
CC       {ECO:0000250|UniProtKB:Q62077}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/plcg1/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M34667; AAA36452.1; -; mRNA.
DR   EMBL; DQ297143; ABB84466.1; -; Genomic_DNA.
DR   EMBL; AL022394; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471077; EAW75991.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW75992.1; -; Genomic_DNA.
DR   EMBL; BC136466; AAI36467.1; -; mRNA.
DR   EMBL; BC144136; AAI44137.1; -; mRNA.
DR   CCDS; CCDS13313.1; -. [P19174-2]
DR   CCDS; CCDS13314.1; -. [P19174-1]
DR   PIR; A36466; A36466.
DR   RefSeq; NP_002651.2; NM_002660.2. [P19174-2]
DR   RefSeq; NP_877963.1; NM_182811.1. [P19174-1]
DR   PDB; 1HSQ; NMR; -; A=790-851.
DR   PDB; 2HSP; NMR; -; A=790-851.
DR   PDB; 4EY0; X-ray; 2.80 A; A/B/C/D=545-790.
DR   PDB; 4FBN; X-ray; 2.40 A; A=545-790.
DR   PDBsum; 1HSQ; -.
DR   PDBsum; 2HSP; -.
DR   PDBsum; 4EY0; -.
DR   PDBsum; 4FBN; -.
DR   SMR; P19174; -.
DR   BioGRID; 111351; 158.
DR   CORUM; P19174; -.
DR   DIP; DIP-100N; -.
DR   IntAct; P19174; 136.
DR   MINT; P19174; -.
DR   STRING; 9606.ENSP00000244007; -.
DR   BindingDB; P19174; -.
DR   ChEMBL; CHEMBL3964; -.
DR   MoonDB; P19174; Predicted.
DR   iPTMnet; P19174; -.
DR   PhosphoSitePlus; P19174; -.
DR   BioMuta; PLCG1; -.
DR   DMDM; 130225; -.
DR   CPTAC; CPTAC-1738; -.
DR   EPD; P19174; -.
DR   jPOST; P19174; -.
DR   MassIVE; P19174; -.
DR   MaxQB; P19174; -.
DR   PaxDb; P19174; -.
DR   PeptideAtlas; P19174; -.
DR   PRIDE; P19174; -.
DR   ProteomicsDB; 53635; -. [P19174-1]
DR   ProteomicsDB; 53636; -. [P19174-2]
DR   ABCD; P19174; 1 sequenced antibody.
DR   Antibodypedia; 3796; 1142 antibodies.
DR   DNASU; 5335; -.
DR   Ensembl; ENST00000244007; ENSP00000244007; ENSG00000124181. [P19174-2]
DR   Ensembl; ENST00000373271; ENSP00000362368; ENSG00000124181. [P19174-1]
DR   GeneID; 5335; -.
DR   KEGG; hsa:5335; -.
DR   UCSC; uc002xjo.2; human. [P19174-1]
DR   CTD; 5335; -.
DR   DisGeNET; 5335; -.
DR   GeneCards; PLCG1; -.
DR   HGNC; HGNC:9065; PLCG1.
DR   HPA; ENSG00000124181; Low tissue specificity.
DR   MIM; 172420; gene.
DR   neXtProt; NX_P19174; -.
DR   OpenTargets; ENSG00000124181; -.
DR   PharmGKB; PA33392; -.
DR   VEuPathDB; HostDB:ENSG00000124181.14; -.
DR   eggNOG; KOG1264; Eukaryota.
DR   GeneTree; ENSGT00940000158901; -.
DR   HOGENOM; CLU_002738_5_0_1; -.
DR   InParanoid; P19174; -.
DR   OMA; YGGKKQH; -.
DR   OrthoDB; 368239at2759; -.
DR   PhylomeDB; P19174; -.
DR   TreeFam; TF313216; -.
DR   BRENDA; 3.1.4.11; 2681.
DR   PathwayCommons; P19174; -.
DR   Reactome; R-HSA-1169408; ISG15 antiviral mechanism.
DR   Reactome; R-HSA-1236382; Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants.
DR   Reactome; R-HSA-1251932; PLCG1 events in ERBB2 signaling.
DR   Reactome; R-HSA-1489509; DAG and IP3 signaling.
DR   Reactome; R-HSA-167021; PLC-gamma1 signalling.
DR   Reactome; R-HSA-1855204; Synthesis of IP3 and IP4 in the cytosol.
DR   Reactome; R-HSA-186763; Downstream signal transduction.
DR   Reactome; R-HSA-202433; Generation of second messenger molecules.
DR   Reactome; R-HSA-2029485; Role of phospholipids in phagocytosis.
DR   Reactome; R-HSA-210990; PECAM1 interactions.
DR   Reactome; R-HSA-212718; EGFR interacts with phospholipase C-gamma.
DR   Reactome; R-HSA-2424491; DAP12 signaling.
DR   Reactome; R-HSA-2871796; FCERI mediated MAPK activation.
DR   Reactome; R-HSA-2871809; FCERI mediated Ca+2 mobilization.
DR   Reactome; R-HSA-418890; Role of second messengers in netrin-1 signaling.
DR   Reactome; R-HSA-5218921; VEGFR2 mediated cell proliferation.
DR   Reactome; R-HSA-5637810; Constitutive Signaling by EGFRvIII.
DR   Reactome; R-HSA-5654219; Phospholipase C-mediated cascade: FGFR1.
DR   Reactome; R-HSA-5654221; Phospholipase C-mediated cascade, FGFR2.
DR   Reactome; R-HSA-5654227; Phospholipase C-mediated cascade, FGFR3.
DR   Reactome; R-HSA-5654228; Phospholipase C-mediated cascade, FGFR4.
DR   Reactome; R-HSA-5655253; Signaling by FGFR2 in disease.
DR   Reactome; R-HSA-5655291; Signaling by FGFR4 in disease.
DR   Reactome; R-HSA-5655302; Signaling by FGFR1 in disease.
DR   Reactome; R-HSA-8853338; Signaling by FGFR3 point mutants in cancer.
DR   Reactome; R-HSA-8853659; RET signaling.
DR   Reactome; R-HSA-9026527; Activated NTRK2 signals through PLCG1.
DR   Reactome; R-HSA-9027277; Erythropoietin activates Phospholipase C gamma (PLCG).
DR   Reactome; R-HSA-9034793; Activated NTRK3 signals through PLCG1.
DR   Reactome; R-HSA-9664323; FCGR3A-mediated IL10 synthesis.
DR   Reactome; R-HSA-9664565; Signaling by ERBB2 KD Mutants.
DR   Reactome; R-HSA-9665348; Signaling by ERBB2 ECD mutants.
DR   Reactome; R-HSA-9665686; Signaling by ERBB2 TMD/JMD mutants.
DR   SignaLink; P19174; -.
DR   SIGNOR; P19174; -.
DR   BioGRID-ORCS; 5335; 18 hits in 999 CRISPR screens.
DR   ChiTaRS; PLCG1; human.
DR   EvolutionaryTrace; P19174; -.
DR   GeneWiki; PLCG1; -.
DR   GenomeRNAi; 5335; -.
DR   Pharos; P19174; Tchem.
DR   PRO; PR:P19174; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   RNAct; P19174; protein.
DR   Bgee; ENSG00000124181; Expressed in left lobe of thyroid gland and 231 other tissues.
DR   ExpressionAtlas; P19174; baseline and differential.
DR   Genevisible; P19174; HS.
DR   GO; GO:0042995; C:cell projection; IDA:BHF-UCL.
DR   GO; GO:0005911; C:cell-cell junction; IEA:Ensembl.
DR   GO; GO:0008180; C:COP9 signalosome; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:MGI.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl.
DR   GO; GO:0030027; C:lamellipodium; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0001726; C:ruffle; IDA:UniProtKB.
DR   GO; GO:0098685; C:Schaffer collateral - CA1 synapse; IEA:Ensembl.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0050429; F:calcium-dependent phospholipase C activity; ISS:UniProtKB.
DR   GO; GO:0035254; F:glutamate receptor binding; IEA:Ensembl.
DR   GO; GO:0005168; F:neurotrophin TRKA receptor binding; IPI:UniProtKB.
DR   GO; GO:0004435; F:phosphatidylinositol phospholipase C activity; IDA:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:BHF-UCL.
DR   GO; GO:0030971; F:receptor tyrosine kinase binding; IEA:Ensembl.
DR   GO; GO:0007202; P:activation of phospholipase C activity; TAS:Reactome.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0019722; P:calcium-mediated signaling; IMP:BHF-UCL.
DR   GO; GO:0016477; P:cell migration; IMP:BHF-UCL.
DR   GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; IDA:UniProtKB.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0038096; P:Fc-gamma receptor signaling pathway involved in phagocytosis; TAS:Reactome.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0043647; P:inositol phosphate metabolic process; TAS:Reactome.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0050804; P:modulation of chemical synaptic transmission; IEA:Ensembl.
DR   GO; GO:0002862; P:negative regulation of inflammatory response to antigenic stimulus; TAS:Reactome.
DR   GO; GO:0046488; P:phosphatidylinositol metabolic process; ISS:UniProtKB.
DR   GO; GO:0009395; P:phospholipid catabolic process; IEA:InterPro.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IDA:DFLAT.
DR   GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; IDA:DFLAT.
DR   GO; GO:2000353; P:positive regulation of endothelial cell apoptotic process; IMP:BHF-UCL.
DR   GO; GO:0010634; P:positive regulation of epithelial cell migration; IMP:UniProtKB.
DR   GO; GO:0010863; P:positive regulation of phospholipase C activity; TAS:Reactome.
DR   GO; GO:0051281; P:positive regulation of release of sequestered calcium ion into cytosol; IMP:BHF-UCL.
DR   GO; GO:1905564; P:positive regulation of vascular endothelial cell proliferation; IMP:BHF-UCL.
DR   GO; GO:0007165; P:signal transduction; TAS:Reactome.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   CDD; cd09932; SH2_C-SH2_PLC_gamma_like; 1.
DR   CDD; cd10341; SH2_N-SH2_PLC_gamma_like; 1.
DR   CDD; cd11970; SH3_PLCgamma1; 1.
DR   Gene3D; 2.30.29.30; -; 1.
DR   Gene3D; 2.60.40.150; -; 1.
DR   Gene3D; 3.20.20.190; -; 2.
DR   Gene3D; 3.30.505.10; -; 2.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR035892; C2_domain_sf.
DR   InterPro; IPR011992; EF-hand-dom_pair.
DR   InterPro; IPR018247; EF_Hand_1_Ca_BS.
DR   InterPro; IPR002048; EF_hand_dom.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR001192; PI-PLC_fam.
DR   InterPro; IPR016279; PLC-gamma.
DR   InterPro; IPR028380; PLC-gamma1.
DR   InterPro; IPR035023; PLC-gamma_C-SH2.
DR   InterPro; IPR035024; PLC-gamma_N-SH2.
DR   InterPro; IPR017946; PLC-like_Pdiesterase_TIM-brl.
DR   InterPro; IPR035724; PLCgamma1_SH3.
DR   InterPro; IPR000909; PLipase_C_PInositol-sp_X_dom.
DR   InterPro; IPR001711; PLipase_C_Pinositol-sp_Y.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR036028; SH3-like_dom_sf.
DR   InterPro; IPR001452; SH3_domain.
DR   PANTHER; PTHR10336; PTHR10336; 1.
DR   PANTHER; PTHR10336:SF173; PTHR10336:SF173; 1.
DR   Pfam; PF00168; C2; 1.
DR   Pfam; PF00388; PI-PLC-X; 1.
DR   Pfam; PF00387; PI-PLC-Y; 1.
DR   Pfam; PF00017; SH2; 2.
DR   Pfam; PF00018; SH3_1; 1.
DR   PIRSF; PIRSF000952; PLC-gamma; 1.
DR   PRINTS; PR00390; PHPHLIPASEC.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   SMART; SM00239; C2; 1.
DR   SMART; SM00233; PH; 3.
DR   SMART; SM00148; PLCXc; 1.
DR   SMART; SM00149; PLCYc; 1.
DR   SMART; SM00252; SH2; 2.
DR   SMART; SM00326; SH3; 1.
DR   SUPFAM; SSF47473; SSF47473; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF51695; SSF51695; 1.
DR   SUPFAM; SSF55550; SSF55550; 2.
DR   PROSITE; PS50004; C2; 1.
DR   PROSITE; PS00018; EF_HAND_1; 1.
DR   PROSITE; PS50222; EF_HAND_2; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 2.
DR   PROSITE; PS50007; PIPLC_X_DOMAIN; 1.
DR   PROSITE; PS50008; PIPLC_Y_DOMAIN; 1.
DR   PROSITE; PS50001; SH2; 2.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Calcium; Cell projection;
KW   Host-virus interaction; Hydrolase; Lipid degradation; Lipid metabolism;
KW   Metal-binding; Phosphoprotein; Reference proteome; Repeat; SH2 domain;
KW   SH3 domain; Transducer; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:19413330"
FT   CHAIN           2..1290
FT                   /note="1-phosphatidylinositol 4,5-bisphosphate
FT                   phosphodiesterase gamma-1"
FT                   /id="PRO_0000088498"
FT   DOMAIN          27..142
FT                   /note="PH 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00145"
FT   DOMAIN          152..187
FT                   /note="EF-hand"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   DOMAIN          320..464
FT                   /note="PI-PLC X-box"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00270"
FT   DOMAIN          489..523
FT                   /note="PH 2; first part"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00145"
FT   DOMAIN          550..657
FT                   /note="SH2 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00191"
FT   DOMAIN          668..756
FT                   /note="SH2 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00191"
FT   DOMAIN          791..851
FT                   /note="SH3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00192"
FT   DOMAIN          895..931
FT                   /note="PH 2; second part"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00145"
FT   DOMAIN          953..1070
FT                   /note="PI-PLC Y-box"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00271"
FT   DOMAIN          1071..1194
FT                   /note="C2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   CA_BIND         165..176
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   ACT_SITE        335
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00270"
FT   ACT_SITE        380
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00270"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0007744|PubMed:19413330"
FT   MOD_RES         506
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q62077"
FT   MOD_RES         771
FT                   /note="Phosphotyrosine; by SYK"
FT                   /evidence="ECO:0000269|PubMed:20494825,
FT                   ECO:0000269|PubMed:8657103, ECO:0007744|PubMed:15144186,
FT                   ECO:0007744|PubMed:19690332"
FT   MOD_RES         775
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         783
FT                   /note="Phosphotyrosine; by ITK, SYK and TXK"
FT                   /evidence="ECO:0000269|PubMed:11564877,
FT                   ECO:0000269|PubMed:15215251, ECO:0000269|PubMed:8657103,
FT                   ECO:0007744|PubMed:19690332"
FT   MOD_RES         977
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q62077"
FT   MOD_RES         1221
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1227
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1233
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1248
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:1370476"
FT   MOD_RES         1253
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:15144186,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         1263
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         1215
FT                   /note="K -> KQ (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_038692"
FT   VARIANT         209
FT                   /note="T -> N (in dbSNP:rs2229348)"
FT                   /evidence="ECO:0000269|Ref.2"
FT                   /id="VAR_025213"
FT   VARIANT         279
FT                   /note="S -> G (in dbSNP:rs2228246)"
FT                   /evidence="ECO:0000269|Ref.2"
FT                   /id="VAR_022130"
FT   VARIANT         739
FT                   /note="S -> T (in dbSNP:rs34203315)"
FT                   /evidence="ECO:0000269|Ref.2"
FT                   /id="VAR_025214"
FT   VARIANT         813
FT                   /note="I -> T (in dbSNP:rs753381)"
FT                   /evidence="ECO:0000269|PubMed:15489334, ECO:0000269|Ref.2"
FT                   /id="VAR_011908"
FT   STRAND          551..554
FT                   /evidence="ECO:0007744|PDB:4EY0"
FT   STRAND          556..558
FT                   /evidence="ECO:0007744|PDB:4EY0"
FT   HELIX           561..576
FT                   /evidence="ECO:0007744|PDB:4FBN"
FT   STRAND          583..587
FT                   /evidence="ECO:0007744|PDB:4FBN"
FT   STRAND          589..591
FT                   /evidence="ECO:0007744|PDB:4FBN"
FT   STRAND          595..601
FT                   /evidence="ECO:0007744|PDB:4FBN"
FT   STRAND          604..613
FT                   /evidence="ECO:0007744|PDB:4FBN"
FT   HELIX           615..617
FT                   /evidence="ECO:0007744|PDB:4FBN"
FT   STRAND          620..624
FT                   /evidence="ECO:0007744|PDB:4FBN"
FT   STRAND          627..631
FT                   /evidence="ECO:0007744|PDB:4FBN"
FT   HELIX           632..641
FT                   /evidence="ECO:0007744|PDB:4FBN"
FT   STRAND          644..646
FT                   /evidence="ECO:0007744|PDB:4EY0"
FT   STRAND          649..651
FT                   /evidence="ECO:0007744|PDB:4EY0"
FT   HELIX           662..665
FT                   /evidence="ECO:0007744|PDB:4FBN"
FT   STRAND          669..672
FT                   /evidence="ECO:0007744|PDB:4FBN"
FT   HELIX           675..683
FT                   /evidence="ECO:0007744|PDB:4FBN"
FT   STRAND          690..695
FT                   /evidence="ECO:0007744|PDB:4FBN"
FT   STRAND          701..708
FT                   /evidence="ECO:0007744|PDB:4FBN"
FT   STRAND          711..720
FT                   /evidence="ECO:0007744|PDB:4FBN"
FT   STRAND          723..726
FT                   /evidence="ECO:0007744|PDB:4FBN"
FT   STRAND          729..732
FT                   /evidence="ECO:0007744|PDB:4FBN"
FT   HELIX           734..743
FT                   /evidence="ECO:0007744|PDB:4FBN"
FT   HELIX           758..763
FT                   /evidence="ECO:0007744|PDB:4FBN"
FT   STRAND          792..794
FT                   /evidence="ECO:0007744|PDB:1HSQ"
FT   STRAND          805..809
FT                   /evidence="ECO:0007744|PDB:1HSQ"
FT   STRAND          817..820
FT                   /evidence="ECO:0007744|PDB:2HSP"
FT   TURN            825..827
FT                   /evidence="ECO:0007744|PDB:1HSQ"
FT   STRAND          834..836
FT                   /evidence="ECO:0007744|PDB:1HSQ"
FT   TURN            843..845
FT                   /evidence="ECO:0007744|PDB:1HSQ"
FT   MOD_RES         P19174-2:1222
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:21406692"
SQ   SEQUENCE   1290 AA;  148532 MW;  AE05ABE2A18EDDAC CRC64;
     MAGAASPCAN GCGPGAPSDA EVLHLCRSLE VGTVMTLFYS KKSQRPERKT FQVKLETRQI
     TWSRGADKIE GAIDIREIKE IRPGKTSRDF DRYQEDPAFR PDQSHCFVIL YGMEFRLKTL
     SLQATSEDEV NMWIKGLTWL MEDTLQAPTP LQIERWLRKQ FYSVDRNRED RISAKDLKNM
     LSQVNYRVPN MRFLRERLTD LEQRSGDITY GQFAQLYRSL MYSAQKTMDL PFLEASTLRA
     GERPELCRVS LPEFQQFLLD YQGELWAVDR LQVQEFMLSF LRDPLREIEE PYFFLDEFVT
     FLFSKENSVW NSQLDAVCPD TMNNPLSHYW ISSSHNTYLT GDQFSSESSL EAYARCLRMG
     CRCIELDCWD GPDGMPVIYH GHTLTTKIKF SDVLHTIKEH AFVASEYPVI LSIEDHCSIA
     QQRNMAQYFK KVLGDTLLTK PVEISADGLP SPNQLKRKIL IKHKKLAEGS AYEEVPTSMM
     YSENDISNSI KNGILYLEDP VNHEWYPHYF VLTSSKIYYS EETSSDQGNE DEEEPKEVSS
     STELHSNEKW FHGKLGAGRD GRHIAERLLT EYCIETGAPD GSFLVRESET FVGDYTLSFW
     RNGKVQHCRI HSRQDAGTPK FFLTDNLVFD SLYDLITHYQ QVPLRCNEFE MRLSEPVPQT
     NAHESKEWYH ASLTRAQAEH MLMRVPRDGA FLVRKRNEPN SYAISFRAEG KIKHCRVQQE
     GQTVMLGNSE FDSLVDLISY YEKHPLYRKM KLRYPINEEA LEKIGTAEPD YGALYEGRNP
     GFYVEANPMP TFKCAVKALF DYKAQREDEL TFIKSAIIQN VEKQEGGWWR GDYGGKKQLW
     FPSNYVEEMV NPVALEPERE HLDENSPLGD LLRGVLDVPA CQIAIRPEGK NNRLFVFSIS
     MASVAHWSLD VAADSQEELQ DWVKKIREVA QTADARLTEG KIMERRKKIA LELSELVVYC
     RPVPFDEEKI GTERACYRDM SSFPETKAEK YVNKAKGKKF LQYNRLQLSR IYPKGQRLDS
     SNYDPLPMWI CGSQLVALNF QTPDKPMQMN QALFMTGRHC GYVLQPSTMR DEAFDPFDKS
     SLRGLEPCAI SIEVLGARHL PKNGRGIVCP FVEIEVAGAE YDSTKQKTEF VVDNGLNPVW
     PAKPFHFQIS NPEFAFLRFV VYEEDMFSDQ NFLAQATFPV KGLKTGYRAV PLKNNYSEDL
     ELASLLIKID IFPAKENGDL SPFSGTSLRE RGSDASGQLF HGRAREGSFE SRYQQPFEDF
     RISQEHLADH FDSRERRAPR RTRVNGDNRL
//
